IMC Logo.jpg
Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering
23. Juli 2020 12:45 ET | Immuron Limited
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing...
IMC Logo.jpg
Immuron Announces $20.0 Million Registered Direct Offering
21. Juli 2020 08:45 ET | Immuron Limited
MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
IMC Logo.jpg
Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points
21. Juli 2020 07:00 ET | Immuron Limited
Immuron’s IMM-124E used to manufacture Travelan® and Protectyn® demonstrates antiviral activity against the COVID-19 virus in laboratory studiesImmuron’s technology platform offers a potential new...
IMC Logo.jpg
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
20. Juli 2020 06:00 ET | Immuron Limited
Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial will...
IMC Logo.jpg
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
19. Juni 2020 06:00 ET | Immuron Limited
Key Points Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc.Immuron executes a Research Agreement with CSIRO to develop a new oral...
IMC Logo.jpg
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea
09. Juni 2020 06:00 ET | Immuron Limited
Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial...
IMC Logo.jpg
Immuron Board Relinquish Cash Payment of Fees
28. April 2020 06:00 ET | Immuron Limited
MELBOURNE, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
IMC Logo.jpg
Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%
20. April 2020 06:00 ET | Immuron Limited
Key Highlights: North American sales up by 95% YoY in Q3 FY20Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20.YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57%...
IMC Logo.jpg
Resignation of CEO & Director and cost cutting amidst COVID-19
25. März 2020 06:00 ET | Immuron Limited
MELBOURNE, Australia, March 25, 2020 (GLOBE NEWSWIRE) -- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the...
IMC Logo.jpg
Immuron Provides Update on First Half of FY20 Results
03. März 2020 07:00 ET | Immuron Limited
Key Highlights: Strong continued growth of Travelan® sales reported in all marketsGlobal sales reached USD $1.1 million (AUD $1.68 million) for first half FY 2020 up 55% from first half FY 2019North...